Weight-Loss Injection: Side Effects in Context
The most common side effects are gastrointestinal, mostly mild and early on. What is actually behind nausea, the gallbladder and pancreatitis, without downplaying and without scaremongering.
Hardly any question moves people before starting a weight-loss injection as much as this one: what will it do to me? The answer is neither harmless nor alarming. The most common side effects affect the gastrointestinal tract, and they are mostly mild and temporary. Rarer topics such as the gallbladder and pancreas deserve a calm, honest appraisal.
This article looks soberly at the data. It is about Ozempic and Wegovy (active ingredient semaglutide) and about Mounjaro (active ingredient tirzepatide). How the injection works is the subject of a separate article. Here it is only about the question of tolerability. I want neither to frighten you nor to gloss over anything. I want to help you put the side effects in context so you can make an informed decision with your doctor.
Side effects are no reason to demonise an effective medication, and no detail to wave away. Both would be dishonest. Most complaints are manageable and dose-dependent. Even so, the injection belongs in medical hands, and for some people it is not the right choice.
The most common topic: the gastrointestinal tract
When people tell me about side effects of the weight-loss injection, it is almost always the same thing: nausea, sometimes vomiting, diarrhoea or constipation. This is no surprise but the logical flip side of the mechanism. The injection slows gastric emptying and amplifies a satiety signal. Food stays in the stomach longer. This keeps you full for longer, but it can also upset the stomach.
A pooled analysis of large approval trials shows just how common this is. These figures are the core when you want to put the weight-loss injection and its side effects in context.
In a pooled analysis of the STEP 1 to 3 trials, the gastrointestinal side effects of semaglutide 2.4 mg were captured systematically. The most common were nausea (43.9 percent versus 16.1 percent with placebo), diarrhoea (29.7 versus 15.9 percent), vomiting (24.5 versus 6.3 percent) and constipation (24.2 versus 11.1 percent). Crucial for context: 99.5 percent of these events were non-serious and 98.1 percent mild to moderate. They mostly occurred during or shortly after dose escalation and then often eased again. For you this means: common, but manageable for most people.
DOI: 10.1111/dom.14551This distribution matters. Common does not mean severe. The vast majority of complaints are what doctors call mild to moderate: unpleasant, but without lasting harm and without a hospital stay. And they are clustered in time. They are strongest during the phase in which the dose is slowly increased. This is why the dose is set step by step and under supervision.
Many expect a yes-or-no answer: tolerable or not. The reality is a curve. For most, the beginning is the hardest time. Those who get through the titration phase with medical support often find that the body adjusts and the complaints ease.
How often do side effects lead to stopping?
An honest question deserves an honest number. Side effects are not just a statistical footnote; for some people they lead to ending treatment. But it remains a minority.
A meta-analysis of four randomised trials with over 3,600 people with obesity without diabetes pooled the safety data on semaglutide. Gastrointestinal side effects were around 1.6 times more common than with placebo. The risk of stopping treatment because of side effects was about twice as high (relative risk 2.19). Soberly put, this means: some people do not tolerate the injection well enough to continue. But the large majority manage, often after a bumpy initial phase.
DOI: 10.15605/jafes.037.02.14For a sense of scale, a look at the STEP 1 trial helps, one of the most important studies on the weight-loss injection at all. There, around 4.5 percent of those treated stopped the trial because of gastrointestinal complaints, versus under 1 percent on placebo. That means more than nine out of ten people coped with the complaints well enough that stopping was not necessary.
In the STEP 1 trial, almost 2,000 adults with obesity without diabetes received semaglutide 2.4 mg or placebo over 68 weeks. Weight fell on average by 14.9 percent with semaglutide and by 2.4 percent with placebo. The most common side effects were nausea and diarrhoea, predominantly temporary and mild to moderate. For you this means: a clear effect is offset mainly by an initial gastrointestinal burden, not by a diffuse ongoing risk.
DOI: 10.1056/NEJMoa2032183The gallbladder: a slightly increased risk
Beyond the stomach and intestine there is a second, well-documented topic: the gallbladder. Careful wording matters here, because the figures sound more dramatic at first than they are for the individual.
A large meta-analysis of 76 randomised trials with over 100,000 people examined the link between GLP-1 medications and gallbladder or biliary diseases. The relative risk was raised by about 37 percent (RR 1.37), affecting gallstones, gallbladder inflammation and biliary disease. In the weight-loss trials the risk was more strongly increased (RR 2.29), as it was at higher doses and with longer use. For you this means: the topic is real and dose-dependent, but the absolute risk for the individual remains moderate.
DOI: 10.1001/jamainternmed.2022.0338Why is this mechanistically plausible? Two paths come together. First, GLP-1 slows not only gastric emptying but can also make the gallbladder empty more sluggishly. A gallbladder that contracts less often favours the formation of gallstones. Second, rapid, marked weight loss is itself a known risk factor for gallstones, quite apart from the medication. Both effects pull in the same direction.
A doubled risk sounds alarming. But when a rare event becomes twice as frequent, it is still rare. That is exactly why the question is not only whether a risk is increased, but how high it is for you personally. This weighing-up belongs in the medical conversation.
The pancreas: very rare and unclear
No topic around the weight-loss injection is discussed as often and as anxiously as inflammation of the pancreas, pancreatitis. All the more important is a sober appraisal. In the controlled trials, this signal is very rare and not statistically clear.
A meta-analysis of large cardiovascular trials with GLP-1 medications assessed, among other things, the safety endpoints of pancreatitis and pancreatic cancer. Alongside benefits for cardiovascular and kidney events, it found no increase in pancreatic side effects. This means: in the largest pooled datasets so far, there is no clearly increased risk for the pancreas. Because such events are rare, the statement remains subject to uncertainty.
DOI: 10.1016/S2213-8587(21)00203-5Specifically for tirzepatide, the dual agent in Mounjaro, a meta-analysis of nine randomised trials examined the safety endpoints of pancreatitis and gallbladder or biliary diseases. For pancreatitis, there was no significantly increased risk compared with the control groups. For you this means: even with the newer, more strongly effective agent, the feared inflammation of the pancreas is not clearly increased in studies.
DOI: 10.3389/fendo.2023.1214334In pooled randomised trials the pancreatitis risk is not significantly increased, neither for semaglutide nor for tirzepatide. The gastrointestinal side effects are well quantified and mostly mild. That is solid evidence.
Very rare events are hard to assess with certainty in studies. This is why clinical vigilance remains sensible. Anyone who develops persistent, severe upper abdominal pain should take it seriously and have it assessed medically rather than wait.
Semaglutide and tirzepatide: the same basic pattern
A common misconception is that Mounjaro, because of its stronger effect, is also more dangerous. The data paint a different picture. Tirzepatide acts on two receptors at once and can lower weight even more. But its side-effect profile is essentially the same as semaglutide's: mainly gastrointestinal, mild to moderate, strongest during the titration phase.
In the SURMOUNT-1 trial, over 2,500 adults with obesity without diabetes received tirzepatide in various doses or placebo over 72 weeks. Weight fell at the highest dose by around 20.9 percent versus 3.1 percent with placebo. The side effects were predominantly gastrointestinal, mostly mild to moderate and mainly during the phase of dose escalation. This shows: a stronger effect does not automatically mean a different side-effect profile.
DOI: 10.1056/NEJMoa2206038A direct comparison of the two agents confirms this. In a head-to-head study, tirzepatide was more effective, yet the most common side effects were the same in both groups: complaints in the gastrointestinal area. So when you put the weight-loss injection and its side effects in context, the substance matters less than the shared rule: the gastrointestinal tract speaks up first.
A separate topic: muscle and stopping
Two further questions often come up in connection with side effects, even though strictly speaking they are something else. One concerns muscle loss. With any larger weight loss, part also comes from lean mass; this holds for the injection as for any other weight reduction. Because the topic deserves its own attention, it is covered in the article on muscle loss under the weight-loss injection.
The other question concerns what happens after stopping. This is not a side effect in the narrow sense but a consequence of the fact that the effect is tied to treatment. How you can counter the so-called rebound effect is explored in the article on stopping and the rebound effect.
These medications are prescription-only and belong in medical care. Please never obtain such products without a medical prescription and monitoring. Before a prescription, the benefits, risks, contraindications and your personal situation should be reviewed. Seek medical advice immediately with persistent, severe vomiting or diarrhoea with signs of dehydration, with severe abdominal pain (especially in the upper right abdomen or in the upper abdomen radiating to the back), with yellowing of the skin or eyes, or with persistent fever. In an acute emergency, call the emergency number 112. This article is for information and does not replace a medical examination.
What this means for your decision
Let us sum up, without glossing over and without dramatising. The side effects of the weight-loss injection are well studied. The most common are gastrointestinal complaints, mostly mild and temporary, strongest at the start. The gallbladder risk is slightly increased, especially at higher doses and with longer use. The feared pancreatitis is very rare and not clearly increased in studies, but it remains a reason for medical vigilance.
Conventional medicine does a lot right here when it checks clear indications, doses up slowly and monitors treatment closely; that is sensible and important. What an integrative view can add is attention to the context: a diet that eases the stomach and strengthens the foundations, the preservation of muscle, an eye on sleep and stress. Our work at ViveCura sits at the intersection of the three areas that define the practice: physical health and metabolism, mental health, and a conscious, healthy lifestyle.
And now you know why the side effects of the weight-loss injection are neither a reason to panic nor a detail to look away from. For most people they are manageable and dose-dependent. But they are exactly why this treatment belongs in medical hands and, for some people, is not the right choice. If you would rather support GLP-1 the natural way first, you will find approaches in the article on boosting GLP-1 naturally.
Frequently asked questions
What are the most common side effects of the weight-loss injection?
By far the most common are gastrointestinal complaints. In the pooled analysis of the STEP trials with semaglutide 2.4 mg, treated participants experienced nausea in around 44 percent, diarrhoea in around 30 percent, vomiting in around 25 percent and constipation in around 24 percent, each markedly more often than with placebo. Important for context: almost all of these events were non-serious and mild to moderate. They usually occur early on and during dose escalation, and often ease afterwards.
Why do Ozempic and Wegovy cause nausea?
The active ingredient semaglutide amplifies a natural satiety signal and slows gastric emptying. Food stays in the stomach longer. This keeps you full for longer, but can also cause nausea, bloating or belching. These complaints are strongest during the phase in which the dose is gradually increased. In many people they improve once the body has adjusted to the dose. How to manage them belongs in your medical care.
Are the gastrointestinal side effects dangerous?
Usually not. In the pooled STEP analysis, 99.5 percent of gastrointestinal events were non-serious and 98.1 percent were mild to moderate. They are unpleasant, but manageable for most people. They can become dangerous mainly indirectly, for example through heavy fluid loss with severe vomiting or diarrhoea. Persistent vomiting, signs of dehydration or severe abdominal pain should be assessed by a doctor.
How often do people stop treatment because of side effects?
Markedly more often than with placebo, but it remains a minority. A meta-analysis found roughly twice the risk of stopping treatment because of side effects compared with placebo. In the STEP 1 trial, around 4.5 percent stopped treatment because of gastrointestinal complaints, versus under 1 percent on placebo. That means the large majority tolerate treatment well enough to continue, often after a more difficult initial phase.
Can the weight-loss injection cause gallstones or gallbladder problems?
The risk of gallbladder and biliary diseases is slightly increased. A large meta-analysis of 76 randomised trials found a relative risk raised by about 37 percent, and in the weight-loss trials it was roughly doubled. That sounds like a lot, but the absolute risk for the individual remains moderate. Higher doses and longer use were associated with more events. Mechanistically this fits with slower gallbladder emptying and with rapid weight loss, which can promote gallstones. Severe pain in the upper right abdomen should be assessed by a doctor.
Does the weight-loss injection cause pancreatitis?
Pancreatitis is a very rare and, in the studies, unclear signal. Large pooled analyses of randomised trials found no statistically meaningful increase in the risk of pancreatitis, neither for semaglutide nor for tirzepatide. Because such events are rare, they are hard to assess with certainty. That is why medical vigilance remains sensible. Persistent, severe upper abdominal pain, often radiating to the back and accompanied by nausea, should be assessed by a doctor without delay.
Are the side effects of Mounjaro (tirzepatide) different?
Essentially similar. Tirzepatide acts on two receptors at once and can produce even greater weight loss. But its side-effect profile is mainly gastrointestinal, mild to moderate and strongest during the titration phase, just like semaglutide. Even in a direct comparison of the two agents, the most common side effects in both groups were gastrointestinal. For pancreatitis, a meta-analysis on tirzepatide likewise found no significantly increased risk.
Do the side effects depend on the dose?
Yes, in large part. Gastrointestinal complaints occur most often while the dose is gradually increased and ease afterwards in many people. The gallbladder risk was also greater in the data at higher doses and with longer use. This is precisely why the dose is set slowly and under medical supervision. Specific titration plans belong in individual medical care, not in a blog article.
For whom is the weight-loss injection less suitable because of side effects?
That is always an individual medical decision. Caution or contraindications apply, among others, with certain pre-existing conditions of the pancreas or biliary tract, with certain rare thyroid conditions in the family, during pregnancy and breastfeeding, and with pronounced gastrointestinal disorders. Interactions with other medications also play a role. Before a prescription, the benefits, risks and personal situation should be reviewed. The injection does not replace a medical examination.
When should I seek medical advice immediately for side effects?
With persistent, severe vomiting or diarrhoea with signs of dehydration, with severe abdominal pain, especially in the upper right abdomen or in the upper abdomen radiating to the back, with yellowing of the skin or eyes, with persistent fever, or with any symptoms that worry you. These signs can point to gallbladder or pancreas problems. When in doubt: better to seek medical advice once too often. In an acute emergency, call the emergency number 112.
Read more in the Weight Guide
Sources
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. DOI: 10.1111/dom.14551 [RCT, pooled analysis STEP 1-3]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183 [RCT, n=1961]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038 [RCT, n=2539]
- He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513-519. DOI: 10.1001/jamainternmed.2022.0338 [Meta-analysis, k=76, n=103,371]
- Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662. DOI: 10.1016/S2213-8587(21)00203-5 [Meta-analysis]
- Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785. DOI: 10.1016/S2213-8587(19)30249-9 [Meta-analysis]
- Zhao Z, Tang Y, Hu Y, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. DOI: 10.3389/fendo.2023.1214334 [Meta-analysis, k=9, n=9871]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. DOI: 10.1016/S0140-6736(21)00213-0 [RCT]
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224 [RCT, n=803]
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. DOI: 10.1038/s41591-023-02597-w [RCT, n=579]
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. DOI: 10.15605/jafes.037.02.14 [Meta-analysis, k=4, n=3613]
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. DOI: 10.1056/NEJMoa2416394 [RCT, n=751]